Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging Markets
about
Analysis of cystic fibrosis-associated P67L CFTR illustrates barriers to personalized therapeutics for orphan diseasesBarriers to the Access of Bevacizumab in Patients with Solid Tumors and the Potential Impact of Biosimilars: A Physician Survey.Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars.Pharmacokinetics, efficacy and safety of the rituximab biosimilar CT-P10.Looking to the future and learning lessons from the recent past: changing stakeholder perceptions of biosimilars in cancer.Docetaxel loaded nanostructured lipid carriers functionalized with Trastuzumab (Herceptin) for HER2-positive breast cancer cells.Biosimilars and the extrapolation of indications for inflammatory conditions.Biosimilar biologic drugs: a new frontier in medical care.Drug tendering: drug supply and shortage implications for the uptake of biosimilarsA randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab.Budget Impact Analysis of Biosimilar Trastuzumab for the Treatment of Breast Cancer in Croatia.The evolution of biosimilars in oncology, with a focus on trastuzumab.Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin AmericaAccess to innovative cancer medicines in a middle-income country - the case of Mexico
P2860
Q37269585-F57D0A85-764E-4711-95DC-24BCCEAD120AQ37731321-54A25028-3903-4025-9C38-5D426FBB0E26Q38643555-EBD58E54-D88A-4238-BCD1-E2302A93B3D7Q38647397-8523A396-6FD3-4414-927D-CBE160EB8C24Q38686396-D75BDA49-A378-4900-A23F-F7BE612F5DD1Q38694486-FDBA5CDE-E29F-4837-A395-38CB689B39B0Q38932150-DD14F895-B7E0-4EB7-B0AE-671E606407F3Q39200937-9DA21C62-43E1-4733-A872-8CCE9C83E459Q42370596-E910906F-4544-4C7E-BC69-325A0499093BQ48250617-89DAFB7B-395B-4CD2-8D7D-E8E371DAED2FQ48307011-2D2EAD22-3DC1-4A11-82D8-1167D5265248Q55219324-8FE0416B-23C7-45F3-BB4D-0D1937FDF31FQ57173064-8DD20C08-DD1B-4772-878D-48E57D43721CQ58568145-E5128390-7713-4A2C-A3ED-37BC46155F36
P2860
Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging Markets
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Barriers to the Use of Trastuz ...... ed States and Emerging Markets
@ast
Barriers to the Use of Trastuz ...... ed States and Emerging Markets
@en
Barriers to the Use of Trastuz ...... ed States and Emerging Markets
@nl
type
label
Barriers to the Use of Trastuz ...... ed States and Emerging Markets
@ast
Barriers to the Use of Trastuz ...... ed States and Emerging Markets
@en
Barriers to the Use of Trastuz ...... ed States and Emerging Markets
@nl
prefLabel
Barriers to the Use of Trastuz ...... ed States and Emerging Markets
@ast
Barriers to the Use of Trastuz ...... ed States and Emerging Markets
@en
Barriers to the Use of Trastuz ...... ed States and Emerging Markets
@nl
P2093
P2860
P356
P1433
P1476
Barriers to the Use of Trastuz ...... ed States and Emerging Markets
@en
P2093
Carmen Criscitiello
Ira Jacobs
Philip Lammers
P2860
P304
P356
10.3390/PH7090943
P577
2014-09-17T00:00:00Z